If you'd like to claim this profile on behalf of your company, please Contact Us.
 

Latest news ...

Some of our recent news articles.

 
16
November
2020
16th November 2020
 

Lilly receives FDA emergency use authorization for the treatment of recently diagnosed COVID-19

INDIANAPOLIS, Nov. 9, 2020 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) today granted Emergency Use Authorization (EUA) for Eli Lilly and Company's (NYSE: LLY) investigational neutralizing antibody bamlanivimab (LY-CoV555) 700 mg. Bamlanivimab is authorized for the treatment of mild to moderate COVID-19 in adults and pediatric patients 12 years and older with a positive COVID-19 test, who are at high risk for progressing to severe COVID-19 and/or hospitalization. Bamlanivimab should be administered as soon as possible after a positive COVID-19 test and within 10 days of symptom onset. The authorization allows for the distribution and emergency use of bamlanivimab, which is administered via a single intravenous infusion.

 
Read the full story »
 
 
03
February
2020
03rd February 2020
 

Eli Lilly quarterly profit jumps 33% on strong Trulicity demand

Revenue from psoriasis treatment Taltz also contributes to profit growth

 
Read the full story »
 
 
24
January
2020
24th January 2020
 

Lilly Strengthens Parenteral Manufacturing Operations

Will invest more than $470 million to build new manufacturing facility in North

 
Read the full story »
 
 
02
December
2019
02nd December 2019
 

Lilly announces $400 million capital investment in manufacturing facilities in Indianapolis

INDIANAPOLISNov. 20, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced plans to invest $400 million in its manufacturing facilities at its Lilly Technology Center campus in Indianapolis. The plans are driven by increasing demand for Lilly's current medicines, and they provide additional manufacturing capacity for future medicines coming from Lilly's pipeline. These new investments will create approximately 100 new highly skilled jobs at the company.

 
Read the full story »
 
 
09
January
2019
09th January 2019
 

Eli Lilly to buy cancer pharma company for $8bn

The move to buy Loxo Oncology is the second multibillion-dollar cancer deal of the year by a major US pharma giant

 
Read the full story »
 
 
26
July
2017
26th July 2017
 

Lilly’s catch-up act in psoriasis is working, but now it has to catch up in cancer

eli Lilly has been playing catch-up in the psoriasis market ever since it launched its drug to treat the condition, Taltz, last spring into a crowded field dominated by Novartis’ Cosentyx. But if second-quarter results are any indication, Lilly is proving to be a formidable competitor.
 
Read the full story »
 
 
27
April
2017
27th April 2017
 

Eli Lilly’s profit beats expectations thanks to demand for new drugs

Products including diabetes treatment Trulicity and psoriasis drug Taltz selling well
 
Read the full story »
 
 
19
April
2017
19th April 2017
 

Pfizer's Xeljanz stands to win from Lilly's baricitinib stunner

Eli Lilly & Co.’s Olumiant rejection surprise Friday has one obvious beneficiary: Pfizer and its rival rheumatoid arthritis med, Xeljanz, already set to break the blockbuster barrier this year.
 
Read the full story »
 
 
18
April
2017
18th April 2017
 

Rejection of arthritis drug hits Eli Lilly and Incyte for $6bn

FDA refuses approval for Baricitinib despite European regulators giving it green light
 
Read the full story »
 
 
07
February
2017
07th February 2017
 

Eli Lilly misses estimates as sales of older drugs decline

Earnings report is the first under CEO Dave Ricks
 
Read the full story »
 
 
25
November
2016
25th November 2016
 

Eli Lilly shares slump as Alzheimer’s drug fails clinical trial

Negative outcome of trial on solanezumab to result in fourth-quarter charge of $150m
 
Read the full story »
 
 
27
July
2016
27th July 2016
 

New diabetes and cancer drugs deliver for Eli Lilly

After-tax profit rises 24.5 per cent to $747.7 million in the second quarter
 
Read the full story »
 
 
06
May
2016
06th May 2016
 

Eli Lilly boss keeps R&D at heart of vision for firm’s future

John Lechleiter has guided company through patent expiries and rejuvenated its pipeline
 
Read the full story »
 
 
27
July
2015
27th July 2015
 

Eli Lilly offers evidence of twice-failed solanezumab's impact on Alzheimer's

nvestigators zeroed in on the performance of patients in the initial placebo arm who were later given solanezumab. Looking over the results on two key measures--ADAS-Cog14 (cognition) and the ADCS-iADL (a daily function assessment)--the placebo group was unable to "catch up" to the patients who were provided solanezumab from the get-go. And that steady gap, Lilly asserts, with the two groups declining on parallel tracks, may well illustrate the disease-modifying effect from the amyloid drug--a landmark event for a field that has seen repeated failures over the years.
 
Read the full story »
 
 
08
July
2015
08th July 2015
 

Eli Lilly experimental lung cancer drug raises FDA concerns

Eli Lilly ’s experimental lung cancer drug raised concerns with US regulators that it may increase patients’ risk of suffering potentially deadly blood clots.
The drug, known as necitumumab, improved patients’ overall chances of survival, yet people taking the medicine also experienced more risk, the Food and Drug Administration said in a report on Tuesday.
 
Read the full story »
 
 
 
 
 
 
 
 
 

About Us

SURIMS is the new name for Actex Pharma Services which was a consultancy established in 2003, supporting companies in the identification, qualification and management of quality vendors and suppliers in ingredients and formulations.

The Pharmaceutical Services Directory supports the identification and on-boarding of quality suppliers and also incorporates software features that manage relationships between suppliers and their customers. These include the building and deployment of questionnaires and assessments, electronic signatures and sign-offs and project management between vendor/partner and customer.

Access to the features and software is available on a 'pay as you go' basis, or a customised version can be licensed for your company for its own supplier on-boarding and supplier management activities. Further information on our software services please contact Tel: +353 87 294 0436 or email info@surims.com

 
 
 

Get in Touch

The Pharmaceutical Services Directory
info@surims.com

 
 
 

© 2020 Surims Ltd | All Rights Reserved.